Abstract | BACKGROUND: The treatment of moderate to severe chronic hand dermatitis (CHD) has been advanced with the introduction of alitretinoin (9-cis-retinoic acid). Although clinical trial data demonstrated the efficacy and safety of alitretinoin, real-world experience is lacking in a more generalized patient population. OBJECTIVE: Patients with CHD often, and unsuccessfully, attempt several therapeutic options before seeing a dermatologist. This chart review study aimed to examine the experience of using alitretinoin for CHD in a dermatology office setting. METHODS: A retrospective chart review of electronic medical records was conducted of all patients prescribed alitretinoin in a community dermatology practice. RESULTS:
Alitretinoin was well tolerated in this patient population of 53 patients and showed a clinically significant reduction in disease symptoms. CONCLUSION:
Alitretinoin was a safe and well-tolerated treatment with significant clinical improvement in our patient population. Few clinically significant laboratory abnormalities were identified, and only one patient discontinued therapy due to adverse events.
|
Authors | Kaiya Ham, Priya Maini, Melinda J Gooderham |
Journal | Journal of cutaneous medicine and surgery
(J Cutan Med Surg)
Vol. 18
Issue 5
Pg. 332-6
(Oct 2014)
ISSN: 1203-4754 [Print] United States |
PMID | 25186994
(Publication Type: Journal Article)
|
Chemical References |
- Dermatologic Agents
- Alitretinoin
- Tretinoin
|
Topics |
- Adult
- Aged
- Alitretinoin
- Chronic Disease
- Community Health Services
- Dermatologic Agents
(adverse effects, therapeutic use)
- Dermatology
- Female
- Hand Dermatoses
(drug therapy)
- Humans
- Male
- Middle Aged
- Retreatment
- Retrospective Studies
- Treatment Outcome
- Tretinoin
(adverse effects, therapeutic use)
|